Kyntra BIO, Inc. $KYNB

What the company doesAI summary of filing

Kyntra Bio is a biopharmaceutical company developing therapies in oncology and anemia. The company's lead program is FG-3246, a potential first-in-class antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer, currently in a Phase 2 monotherapy dose optimization study with interim results expected in the second half of 2026. Kyntra Bio also retains rights to roxadustat, an oral small-molecule therapy approved in Europe, Japan, China and other countries for treating anemia in chronic kidney disease patients; the company is preparing for a Phase 3 trial of roxadustat for anemia associated with lower-risk myelodysplastic syndromes following a positive FDA Type-C meeting in July 2025. The company generates revenue primarily through collaboration agreements with Astellas and AstraZeneca for roxadustat development and commercialization, and is at the clinical-stage for its oncology program while advancing late-stage development for its MDS indication. [10-K 2026-03-16]

Segments: FG-3246 and FG-3180 (CD46-targeted ADC and PET imaging agent for mCRPC), Roxadustat for anemia in chronic kidney disease, Roxadustat for anemia associated with myelodysplastic syndromes